Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Diflunisal in HIV-infected Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women aged 19 years or over~2. HIV positive by ELISA and Western blot, at least 3 months prior to screening~3. No antiretroviral therapy within 3 months prior to screening~4. Plasma HIV RNA (viral load) \> 2,500 copies/mL at screening~5. Current CD4 cell count \>350 cells/mm3 at screening~6. Adequate renal function as demonstrated by eGFR \>60 mL/min. at screening~Exclusion Criteria:~1. Pregnancy or breast-feeding~2. Any HIV-associated symptom or condition (e.g. nephropathy) for which standard antiretroviral therapy is indicated immediately~3. History of peptic ulcer and/or gastrointestinal bleeding~4. Allergy to ASA, other salicylates, or NSAIDs~5. Currently receiving treatment with an ACE inhibitor, ASA, anticoagulants, antacids containing aluminum hydroxide, cyclosporine, diuretics, systemic glucocorticoids, lithium, methotrexate, or other NSAIDs~6. Significant hepatic impairment or active liver disease - screening AST, ALT, or bilirubin \>2.5x upper limit of normal (ULN)~7. Hyperkalemia - screening serum potassium \>5.5 mmol/L~8. Anemia - screening hemoglobin \<85 g/L

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diflunisal (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).